Our services: capital raising for fast growing companies

eTheRNA is a clinical-stage mRNA companies in the European healthcare sector. The company has mRNA technology discovery and development capabilities with a full platform of integrated capabilities, including own manufacturing.
As the company’s current investors were already mostly the European Tier-I healthcare investors,  the company wanted to attract new investors for their € 39M Series B, and at the same gain access to the Asian market.

What we did and delivered

  • Given the company’s global cutting-edge technology and great opportunities globally, eTheRNA had a competitive advantage in China.  Partnering with Chinese pharma companies was the best way forward to gain access to the Chinese market 
  • We successfully brought in a Chinese strategic lead investor & two follow investors for the €39M Series B
  • We brokered the Licensing & Joint Venture deal with Grand Pharma (0512.HK)


  • eTheRNA completed its Series B and later on its Series C
  • Via its Joint Venture in China the company has now manufacturing and product development capabilities, important to launch its products locally
More on subject(s)   Follow us at LinkedIn

Stay up to date